1	Laboratory-confirmed respiratory viral infection triggers for acute myocardial infarction and
2	stroke: systematic review protocol

3 Short title: systematic review protocol of viral triggers for acute cardiovascular events

- 5 Tu Q Nguyen^{1,2*}, Diana Vlasenko^{2,3}, Aishwarya N Shetty^{2,3}, Christopher M Reid^{,4,5}, Hazel J
 6 Clothier^{1,2,3,6}, Jim P Buttery^{1,2,3,7}
- 7 ¹ Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia
- 8 ² Epi-Informatics, Murdoch Childrens Research Institute, Centre for Health Analytics,
- 9 Melbourne Children's Campus, Melbourne, Victoria, Australia
- ³ Epi-Informatics group and SAEFVIC, Murdoch Children's Research Institute, 50
- 11 Flemington Rd, Parkville, Victoria, Australia
- ⁴ School of Population Health, Curtin University, Perth, Western Australia, Australia
- 13 ⁵ Centre for Cardiovascular Research and Education in Therapeutics, Monash University,
- 14 Melbourne, Victoria, Australia
- ⁶ School of Population and Global Health, The University of Melbourne, Melbourne,

16 Vie	toria, Australia
--------	------------------

- ⁷ Department of Infectious Diseases, Royal Children's Hospital, Melbourne, Victoria,
 Australia
- 19

20 * Corresponding author

21 Email: <u>tun1@student.unimelb.edu.au</u> (TQN)

22 Abstract

23 Background

24 Cardiovascular disease contributes substantially to global mortality and morbidity. 25 Respiratory tract infections, particularly influenza, may trigger an increase in the short-term 26 risk of acute myocardial infarction and stroke. Recent studies have also linked this risk to 27 other respiratory viruses, including respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the pathogen-specific relative 28 29 contributions, the strength of their associations, and overall public health significance are 30 poorly understood. Assuming causal links, understanding, quantifying, and comparing the 31 effects of different pathogens as triggering factors for acute cardiovascular events is critical 32 to guide future research and prevention. Our aim is to conduct a systematic review to 33 examine the relative effects of laboratory-confirmed respiratory virus infections as triggers 34 for acute myocardial infarction and stroke.

35 Methods

We will conduct a comprehensive search of Ovid MEDLINE, PubMed, Ovid Embase,
Cochrane Library Central Register of Controlled Trials, and Web of Science, from inception
to the end of March 2024. We will include the following analytical epidemiological study
types: randomised controlled trials, cohort and case-control studies, self-controlled case
series, and case-crossover designs. We will not impose restrictions on the date, language,
geographical region, or sample size, to minimise the risk of introducing biases. Search results
will be screened for eligibility by two independent reviewers, and discrepancies resolved by

consensus and/or arbitration by a third reviewer. We will assess the risk of bias among the
included studies by adopting the Cochrane Collaboration tools for randomised and nonrandomised studies. The overall quality of studies will be assessed using the Grading of
Recommendations, Assessment, Development and Evaluations (GRADE) approach. We will
examine sources of heterogeneity, and if studies are sufficiently homogeneous, a metaanalysis will be conducted to calculate the pooled effect sizes. Reporting will adhere to the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

50 **Registration**

- 51 International Prospective Register of Systematic Reviews (PROSPERO) registration number:
- 52 CRD42024494997

53 Introduction

54 Rationale

55 Cardiovascular disease (CVD), particularly acute myocardial infarction (AMI) and stroke, 56 remains the world's leading contributor of disease burden and death.[1] Despite progress in 57 age-standardised mortality rates, the prevalence and incidence of acute cardiovascular events 58 is set to rise due to increasing urbanisation, population growth and ageing.[2] Well-59 established risk factors include air pollution, smoking, poor diet, hypertension, and physical 60 inactivity,[3,4] which explain most but not all of the attributable cardiovascular disease 61 burden. It is thought that precipitating factors such as mental stress, physical exertion, certain drugs and infections may 'trigger' susceptible individuals to experience AMI or stroke.[5] 62 63 Gaining insight into the role of these factors is crucial for improved risk prediction and 64 prevention.

65

66 Given the prevalence of infections, strong biological plausibility, and apparent reduction in 67 acute cardiovascular outcomes observed in influenza vaccine randomised controlled trials,[6-8] the contribution to the burden of cardiovascular disease may be substantial. To date, 68 69 reliable data are largely obtained from epidemiological studies focusing on individuals with 70 influenza infection[9]; however, other small-scale studies have described the effects of 71 various bacterial and viral infections on specific cardiovascular endpoints.[10-12] Infections 72 involving the lower and upper respiratory tract are most frequently implicated as triggers for 73 AMI and stroke; attributable respiratory viruses include influenza, respiratory syncytial virus 74 (RSV),[10,11] cytomegalovirus (CMV),[12] and more recently, severe acute respiratory

syndrome coronavirus 2 (SARS-CoV-2).[13] Respiratory viruses can infiltrate the lungs
through airway epithelial cells, directly stimulating the production of proinflammatory
cytokines. The hypothesis is that this triggers systemic inflammation, inducing endothelium
damage, atherosclerosis and plaque rupture,[14] increasing the risk of AMI and stroke.[15]
The duration of the risk period following respiratory infection is typically brief, lasting from
several days to a few months, and gradually diminishes with reduced viral load.[16,17]

81 Given the evidence of a protective relationship between influenza vaccine and cardiovascular 82 disease risk, [18,19] high-quality observational studies of other viral precipitants could pave 83 the way for future trials beyond influenza. However, the comparative pathogen-specific effects of respiratory viruses on the risk of AMI and stroke remain unclear. Modern 84 85 diagnostic tests, such as increasingly available multiplex respiratory panels, enable the 86 distinction between potentially attributable viruses. Previous systematic reviews and meta-87 analyses have focused solely on a single viral trigger like influenza or SARS-CoV-2,[20,21] 88 or relied on broad definitions of infection (e.g. symptomatic respiratory tract infection or 89 influenza-like illness),[22] making interpretation challenging as data were not pooled across 90 studies detecting different attributable viruses.[23] In this systematic review, we aim to 91 examine the evidence from studies of respiratory viruses identified by laboratory-92 confirmatory testing, compare the associations between viral respiratory triggers, and 93 estimate the pooled pathogen-specific effects on acute myocardial infarction and stroke 94 events.

95

96 **Objectives**

97 Our objective is to systematically review the associations between acute myocardial 98 infarction/stroke and laboratory-confirmed respiratory viral infection. This will be addressed 99 through a comprehensive search of analytical epidemiological evidence in humans of any age 100 or geographical region, specifically published studies that capture laboratory-confirmed 101 respiratory viral infections and their effects on acute myocardial infarction or stroke 102 outcomes. A secondary objective is to identify gaps in the literature, assess the certainty of 103 the evidence, and recommend areas for future research.

104

105 Methods

106 The systematic review has been registered with the International Prospective Register of

107 Systematic Reviews (PROSPERO). Important protocol amendments will be explained,

108 including the date and reason for the amendment, in the completed published review, in

addition to the tracking in PROSPERO.

110 Eligibility criteria

111 The eligibility criteria based on the Population, Intervention/Exposure, Comparison,

112 Outcome, Study design, and Timeframe (PICOST) approach, with "intervention" replaced by

113 "exposure", are as follows:

114 **Population:** Studies involving human participants of any age in any country or region. All

115 healthcare or community settings (e.g. hospital admission, emergency department, ambulance

116 attendances, and primary care consultations) will be considered.

117 Exposure: Laboratory-confirmed respiratory viral infection. We will consider viruses that 118 primarily cause illnesses affecting the nose, throat, mouth, and breathing passages, such as 119 common cold or flu-like symptoms. Respiratory viruses include (but are not limited to): 120 influenza, parainfluenza, RSV, human metapneumovirus, rhinovirus, adenovirus, and SARS-CoV-2. Bacteria (including mollicutes) or fungi are excluded. Studies will only be included 121 122 in which the specific causative microorganism(s) are reported, as detected by confirmatory 123 laboratory methods, including polymerase chain reaction (PCR) and serological tests, but 124 exclude point-of-care testing such as rapid antigen tests. Suspected infection, influenza-like 125 illness, or unspecified respiratory tract infections in the absence of laboratory-confirmed results, are excluded. We will exclude viruses that do not primarily result in respiratory 126 127 phenotypes, such as human immunodeficiency virus (HIV), viral hepatitis, dengue virus, 128 Ebola virus, and other viral haemorrhagic fevers. Latent or persistent viral exposure, such as 129 human herpesviruses detected solely by serum IgG antibodies, will be excluded.

130 **Comparator:**

131 Eligible studies must include a comparator group that is unexposed, that is, without 132 respiratory infection, negative testing individuals, or non-active/latent infection. This includes 133 individuals with negative laboratory test result(s), an infection-free group in cohort and case-134 control studies, or unexposed person-time in case-only studies. In randomised controlled 135 trials (RCTs) testing specific anti-infective interventions, such as influenza vaccine studies, 136 data will be treated observationally, that is, the comparator group will be considered regardless of treatment allocation. Before and after (pre-post) COVID-19 pandemic 137 138 comparators are excluded to ensure all groups have similar chance of exposure to the 139 circulating respiratory virus.

140 Outcome: Fatal and non-fatal incidence of AMI or stroke (ischaemic or haemorrhagic), 141 either first or recurrent events. Studies will be included if both or one of these conditions is 142 measured, that is, either AMI or stroke. Diagnosis may be clinical, routinely coded, or self-143 reported. Patients with composite acute cardiovascular or cerebrovascular outcomes, but not 144 exclusively AMI or stroke, will be excluded. We will exclude transient ischaemic attacks and 145 other neurological or thrombotic conditions in which AMI or stroke is not specifically 146 mentioned, such as unstable angina, cardiac arrest, congestive heart failure or 147 cardiomyopathy, peripheral arterial disease, or venous thromboembolism. Cardiovascular or 148 cerebrovascular inflammatory conditions of infectious origin, such as myocarditis, 149 encephalitis, meningitis, or endocarditis, will be excluded. RCTs capturing adverse events 150 following vaccination and surgical or pharmacological complications will be excluded if 151 AMI or stroke is not the primary outcome. Studies assessing only intermediate outcomes such 152 as inflammatory biomarkers are also excluded.

153 Study design: Primary research papers describing RCTs, cohort and case-control studies, 154 self-controlled case series, and case crossover designs. RCTs will be included where there are 155 arm-specific data for the effect of infection for the effect of infection on the risk of incident 156 AMI and/or stroke. Cross-sectional study designs, uncontrolled before-after studies including 157 interrupted time series, ecological studies, case reports, or case series of individual patients, 158 and reviews will be excluded. Studies must report the effect estimates (risk ratio, odds ratio, 159 rate ratio, incidence rate ratio, or hazard ratio) or provide data to calculate an estimate of the 160 effect on the risk of acute myocardial infarction and/or stroke.

161 Timeframe: While there are no time restrictions on the risk window or follow-up period 162 used, we will prioritise studies using short-term risk periods (up to 90 days) of laboratory 163 confirmation i.e. primary outcome occurring within the date of specimen collection. Studies with longer risk periods will be assessed for eligibility considering the risk of bias for
inclusion. This time window focuses on the cardiovascular triggering effect following viral
infection. We will consider contacting corresponding authors to confirm eligibility or to
obtain further information where needed.

168

169 No date, country, geographical, language, publication status or minimum sample size 170 restrictions apply. Studies in which the methods are insufficiently described or without 171 extractable results will be excluded. Refinement of the eligibility criteria is expected to be 172 iterative and depends on the search results identified during screening. We will consider contacting authors for clarification or if further information is needed to confirm eligibility. 173 174 This systematic review will be reported in accordance with the PRISMA guidelines and Meta-analysis of Observational Studies in Epidemiology (MOOSE) statement (if 175 176 applicable).[24,25] Additionally, the current protocol adheres to the Preferred Reporting 177 Items for Systematic Review Protocols (PRISMA-P) 2015 statement (see S1 File for 178 checklist).[26]

179

180 Information sources

181 We will search the following electronic bibliographic databases from their inception until the

182 end of March 2024: MEDLINE (Ovid), Embase (Ovid), PubMed (NLM), Cochrane Central

- 183 Register of Controlled Trials (Wiley), and Web of Science Core Collection (Clarivate
- 184 Analytics). The database selection and search strategy were developed in close consultation
- 185 with an experienced medical/healthcare librarian engaged in the early planning phase. In

186 addition, we will check the reference lists of the included studies (backward citations) and 187 articles that cited the included studies (forward citations) to identify any further relevant 188 papers. Where necessary, investigators will be contacted to request further information about 189 conference abstracts, trial registrations, or unpublished work. A preliminary search of 190 previous systematic reviews on the topic to identify existing or related reviews registered on 191 PROSPERO and via the Cochrane Library has been conducted to avoid duplicating work. 192 Articles cited in previous systematic reviews will be checked to identify any other potentially 193 relevant studies.

194

195 Search strategy

196 The search strategy combines thesaurus terms or Medical Subject Headings (MeSH), where 197 available, and free-text synonyms for search concepts based on the PICOST framework (S2 198 File). A search strategy has been designed based on the Population, Exposure, Outcome and 199 Study design elements using Boolean operators (AND, OR) to combine variations of the 200 following search concepts: "Humans", excluding animal studies; "Laboratory confirmatory 201 tests", including monoplex or multiplex PCR assays, serology, viral culture and 202 immunofluorescence; "respiratory viruses" including influenza viruses, coronaviruses 203 including SARS-CoV-2, picornaviruses (including enteroviruses), human metapneumovirus, RSV, paramyxoviruses (including parainfluenza viruses), adenoviruses, herpes family viruses 204 205 (including herpes simplex virus 1 and 2, varicella zoster virus, Epstein-Barr virus and 206 cytomegalovirus) and human bocavirus; "acute myocardial infarction or stroke" including 207 heart attack, cardiovascular death, ischaemic stroke, haemorrhagic stroke; and from analytical 208 epidemiological study designs. Where thesaurus terms or MeSH exist, for example, virus

209 families covering relevant species or subtypes, these have been exploded to include all 210 narrower terms in the tree (if appropriate). The search is limited to RCTs, cohort, case-211 control, self-controlled case-series and case crossover designs, based on the MEDLINE 212 search filters from BMJ Best Practice for RCTs and epidemiological study designs.[27]. The strategy has been developed initially for MEDLINE via the Ovid interface, then subsequently 213 214 translated into appropriate search terms for the other databases. The Polyglot Search 215 Translator tool was used to assist with translation across from MEDLINE into the Cochrane 216 Library.[28]

217

218 Study records

219 **Data management**

Citations retrieved will be uploaded to Covidence, an online software system used to manage
systematic reviews and promotes collaboration among authors.[29] Duplicates will be
removed using the in-built duplicate feature, and further deduplication by manual review in
Covidence. Upon completion of title and abstract screening, full-text articles will be uploaded
to Covidence for full-text review. The reference management software EndNote X21
(Clarivate Analytics) will be used to manage records outside of Covidence throughout the
review.[30]

227 Selection process

228 The title/abstract screening process will initially be piloted with at least 50 articles to ensure

229 consistent implementation of the eligibility criteria between reviewers. Following

230 deduplication, the search results will be screened for eligibility by two independent reviewers 231 in two stages: title and abstract screening, followed by a review of the full text. Discrepancies 232 in either of the screening stages will be resolved by consensus and/or arbitration by a third reviewer. Inter-rater reliability will be calculated using the Cohen κ value for both stages of 233 screening. Studies determined to be ineligible will be excluded from the review and reasons 234 235 for exclusion at the full-text stage reported in accordance with Preferred Reporting Items for 236 Systematic reviews and Meta-analyses (PRISMA).[24] A PRISMA-compliant flow chart will 237 be used to display the selection of articles with reasons for exclusion.

Data collection process

Data will be extracted using a standardised template based on the PICOST framework using Covidence software. A standardised data collection form in Covidence will initially be piloted on at least 50 of the included studies, and changes to the form will be made if required. We will collect data on study populations, settings, exposure and outcome definitions, outcome measures, effect sizes, confidence intervals, and results of significance testing. The authors of the studies will be contacted if missing data are identified during the data extraction phase.

We will assess the need for double extraction of results if there is sufficient homogeneity for meta-analysis. If meta-analysis is required, we will use double data extraction (of critical data items required for the interpretation of results) performed independently by two people to minimise errors, and discrepancies will be resolved by discussion. Otherwise, data extraction will be performed by one reviewer and checked for accuracy by a second reviewer.

252 **Data items**

253	Data items on the following five domains will be extracted:
254	1. Study characteristics: author(s), publication, year, country, study design, funding source(s)
255	2. Population: characteristics of the study population (e.g., age, sex, country and setting,
256	inclusion and exclusion criteria), sample size, study period, follow-up time (if applicable)
257	3. Exposure: viral respiratory pathogen(s), definition of exposure(s), risk window used, type
258	of laboratory test used, number of exposed subjects
259	4. Comparators: definition of unexposed individuals, number of unexposed subjects,
260	confounders adjusted for
261	5. Outcomes: acute myocardial infarction and/or stroke, outcome definition and method of
262	diagnosis, disease subtype (if applicable), number of subjects with outcome, effective size,
263	95% confidence interval, p-value
264	For studies meeting the inclusion criteria, we will additionally assess mortality outcomes and
265	data among the specific cardiovascular endpoints: ST-elevation myocardial infarction
266	(STEMI) or non-STEMI, and ischaemic or haemorrhagic stroke, if available.
267	
268	Risk of bias in individual studies

- 269 Study-level methodological quality assessment will examine the strength of the evidence
- 270 from individual studies regarding the presence and nature of potential triggering effect(s) of

271 respiratory virus exposure on acute cardiovascular outcomes. We will use the Cochrane 272 Collaboration tools for randomised trials and non-randomised studies, the Cochrane Revised 273 Risk of Bias tool for randomised trials (RoB 2) and the Cochrane Risk of Bias in Nonrandomised studies - of Exposures (ROBINS-E) for observational studies to judge overall 274 risk of bias for each individual study based on study methodology.[31] For RCTs, domains 275 276 will include bias arising from 1) the randomisation process, 2) deviations from intended 277 interventions, 3) missing outcome data, 4) measurement of the outcome and 5) selection of 278 the reported result.[32] For non-randomised studies, the ROBINS-E tool for assessing 279 epidemiological studies of exposure-outcome effects assesses seven domains for bias due to 280 1) confounding, 2) measurement of the exposure, 3) selection of participants into the study or 281 analysis, 4) post-exposure interventions, 5) missing data, 6) measurement of the outcome and 282 7) selection of the reported result.[33]

The risk of bias assessment of the studies will be performed independently by two reviewers, and discrepancies will be resolved through discussion to achieve consensus. However, failing agreement, a third reviewer arbitrates. The overall risk of bias judgement will be categorised as 'low risk of bias', 'some concerns', or 'high risk of bias'. The results will be synthesised into a narrative summary and incorporated into the primary analysis, stratified by outcome and subgroups, if appropriate. A summary table of domain-level judgments will be produced to show how each study fares.

290

291 Data synthesis and meta-bias(es)

All syntheses will be categorised according to their primary outcome (acute myocardial infarction or stroke). Study characteristics and measured outcomes will be compiled into summary tables grouped by outcomes and specific viral pathogens. If the studies are sufficiently homogenous by outcome definition and population, we will combine the data statistically in a meta-analysis. A prerequisite is that the outcome definitions and relative effect measures need to match, and that at least three or more studies report the same outcome to trigger a meta-analysis.

299 For studies of the same primary dichotomous outcomes (acute myocardial infarction or

300 stroke), a forest plot visualisation including confidence intervals, Cochrane's Q test for

301 statistical heterogeneity, and I² statistic will be used to assess between-study

302 heterogeneity.[34] Where appropriate, meta-analysis will be conducted to calculate pooled

303 effect sizes in a fixed-effect or random-effects model.

304 We will investigate sources of heterogeneity for each primary outcome by:

305 a) Sub-group analysis, and

b) Meta-regression, that is, meta-analyses for each subgroup (study design, outcome

307 definition, studies with good/poor control for confounding, effects in older/younger

308 individuals, etc.

309 Factors that may contribute to heterogeneity between studies evaluating the same outcome

310 include: methodological diversity (study design, data source, or setting), study population

311 characteristics (age strata, sex, country, socioeconomic status, and comorbidities), exposure

312 definition (specific virus, laboratory test, or risk window), interventions (vaccinated or

313 unvaccinated), outcome definition (disease, subtype), and diagnosis (clinical diagnosis,

314 administrative data, or self-report).

Where meta-analysis is not appropriate, only a qualitative synthesis is presented. Publication bias will be assessed using funnel plots. If sufficient data are available in the included studies, we will synthesise the answers to our research questions by subgroup. All analyses will be performed in R Statistical Software (v4.3.2 or later).[35]

319

320 Confidence in cumulative evidence

321 The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) 322 approach will be used to assess the certainty of the evidence for each respiratory virus on 323 each individual outcome, by patient population, across the five domains (Risk of bias, 324 inconsistency, indirectness, imprecision and publication bias) for population-level 325 outcomes.[36] The strength of the evidence will be categorised as 'low', 'moderate' or 'high', 326 with observational studies starting as low-quality evidence, but upgraded to moderate or high 327 quality in the presence of other factors that increase confidence in the result e.g. strong 328 association, evidence of dose response gradient. Owing to the life-threatening, critical nature 329 of our primary outcomes, we consider consistent nonzero relative effects (for example, 330 RR>1) and precise estimates to be important. We will report the GRADE assessment in our results stratified by type of exposure with a row for each important outcome (myocardial 331 332 infarction, stroke, or specific subtype), and the strength of the evidence will be presented in a 'Summary of findings' table. This assessment will enable formal judgement of the overall 333

quality of the evidence included in the review, summarising gaps in the literature, and areasfor future research.

336

337 Ethics and dissemination

This review is ongoing. As this is a systematic review, ethical approval is not required. Upon completion, the results will be submitted to a relevant journal for peer-reviewed publication, presented at scientific conferences in this field. A lay and short summary will be displayed in appropriate reports.

342

343 **Conclusion**

Implementing cost-effective policies to avoid premature deaths, disability and unsustainable 344 345 economic costs attributable to acute myocardial infarction and stroke are a global health 346 priority.[37] There is currently indirect epidemiological evidence regarding the immediate triggering effects of influenza and other respiratory viruses, but the pooled pathogen-specific 347 348 risk is unknown. Given the co-circulation of respiratory viruses and their increasing ability to 349 prevent and mitigate symptomatic infections, it is important to quantify the relative effects of 350 causative agents, particularly respiratory viruses, in order to evaluate the risk of cardiovascular outcomes. The findings of this systematic review offer value to clinicians as it 351 352 will provide comprehensive evidence regarding common respiratory virus exposure and risk among high-risk patients. The findings will help to identify candidate pathogens for potential 353 354 vaccine trials or other preventive therapies in targeted populations. Furthermore, where

- 355 attributable pathogens have established vaccines, this could be used for potential vaccine
- 356 probe studies to inform vaccine-preventable cardiovascular burden.[38]

357

358 Acknowledgements

- 359 The authors would like to thank Poh Chua (Librarian, Royal Children's Hospital Melbourne),
- 360 whose advice and guidance were of integral importance in planning and designing the search
- 361 process from the start of the protocol, and Lai-Yang Lee for providing technical expertise in
- 362 interpreting latent viral diagnostics (Medical Microbiologist, Royal Children's Hospital
- 363 Melbourne).

364

365 **References**

366 1. Institute for Health Metrics and Evaluation (IHME). In: Global Burden of Disease (GBD) Compare [Internet]. GBD 2019 [cited 19 Sep 2023]. Available: 367 368 http://vizhub.healthdata.org/gbd-compare 369 2. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. J Am Coll 370 Cardiol. 2020;76: 2982-3021. doi:10.1016/j.jacc.2020.11.010 371 Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially 372 3. 373 modifiable risk factors associated with myocardial infarction in 52 countries (the 374 INTERHEART study): case-control study. The Lancet. 2004;364: 937–952. 375 doi:10.1016/S0140-6736(04)17018-9 376 O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and 4. 377 regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. The Lancet. 2016;388: 761-775. 378 379 doi:10.1016/S0140-6736(16)30506-2

- Schwartz BG, Mayeda GS, Burstein S, Economides C, Kloner RA. When and Why Do
 Heart Attacks Occur? Cardiovascular Triggers and Their Potential Role. Hosp Pract.
 2010;38: 144–152. doi:10.3810/hp.2010.06.308
- Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of
 Myocardial Infarction and Stroke after Acute Infection or Vaccination. N Engl J Med.
 2004;351: 2611–2618. doi:10.1056/NEJMoa041747
- Blackburn R, Zhao H, Pebody R, Hayward A, Warren-Gash C. Laboratory-Confirmed Respiratory Infections as Predictors of Hospital Admission for Myocardial Infarction and Stroke: Time-Series Analysis of English Data for 2004–2015. Clin Infect Dis. 2018;67: 8–17. doi:10.1093/cid/cix1144
- Omidi F, Zangiabadian M, Shahidi Bonjar AH, Nasiri MJ, Sarmastzadeh T. Influenza
 vaccination and major cardiovascular risk: a systematic review and meta-analysis of
 clinical trials studies. Sci Rep. 2023;13: 20235. doi:10.1038/s41598-023-47690-9
- Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et
 al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl
 J Med. 2018;378: 345–353. doi:10.1056/NEJMoa1702090
- Pagliano P, Spera AM, Ascione T, Esposito S. Infections causing stroke or stroke-like
 syndromes. Infection. 2020;48: 323–332. doi:10.1007/s15010-020-01415-6
- Ivey KS, Edwards KM, Talbot HK. Respiratory Syncytial Virus and Associations With
 Cardiovascular Disease in Adults. J Am Coll Cardiol. 2018;71: 1574–1583.
 doi:10.1016/j.jacc.2018.02.013
- Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective Study of Herpes
 Simplex Virus, Cytomegalovirus, and the Risk of Future Myocardial Infarction and
 Stroke. Circulation. 1998;98: 2796–2799. doi:10.1161/01.CIR.98.25.2796
- 404 13. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19.
 405 Nat Med. 2022;28: 583–590. doi:10.1038/s41591-022-01689-3
- 406 14. Gopal R, Marinelli MA, Alcorn JF. Immune Mechanisms in Cardiovascular Diseases
 407 Associated With Viral Infection. Front Immunol. 2020;11: 570681.
 408 doi:10.3389/fimmu.2020.570681
- 409 15. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial
 410 infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis.
 411 2009;9: 601–610. doi:10.1016/S1473-3099(09)70233-6
- 412 16. Blackburn R, Zhao H, Pebody R, Hayward A, Warren-Gash C. Laboratory-Confirmed
 413 Respiratory Infections as Predictors of Hospital Admission for Myocardial Infarction
 414 and Stroke: Time-Series Analysis of English Data for 2004–2015. Clin Infect Dis.
 415 2018;67: 8–17. doi:10.1093/cid/cix1144

- 416
 17. Ohland J, Warren-Gash C, Blackburn R, Mølbak K, Valentiner-Branth P, Nielsen J, et
 417
 al. Acute myocardial infarctions and stroke triggered by laboratory-confirmed
 418
 418
 419
 419
 410
 410
 410
 410
 410
 410
 410
 411
 411
 411
 411
 412
 412
 413
 414
 414
 414
 415
 414
 415
 415
 416
 416
 417
 417
 418
 418
 419
 410
 410
 410
 410
 410
 410
 410
 411
 411
 411
 412
 412
 412
 412
 413
 414
 414
 414
 415
 414
 415
 414
 415
 415
 416
 417
 418
 418
 418
 419
 418
 418
 419
 418
 419
 419
 419
 410
 410
 410
 410
 410
 411
 411
 411
 412
 412
 412
 412
 412
 413
 414
 414
 414
 415
 414
 415
 414
 415
 414
 415
 414
 415
 414
 415
 414
 415
 414
 415
 414
 414
 415
 414
 414
 414
 415
 414
 415
 414
 415
 414
 415
 414
 415
 414
 415
 414
 415
 414
 415
 414
 415
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
 414
- 18. Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for
 preventing cardiovascular disease. Cochrane Heart Group, editor. Cochrane Database
 Syst Rev. 2015;2015. doi:10.1002/14651858.CD005050.pub3
- Fountoulaki K, Tsiodras S, Polyzogopoulou E, Olympios C, Parissis J. Beneficial
 Effects of Vaccination on Cardiovascular Events: Myocardial Infarction, Stroke, Heart
 Failure. Cardiol Int J Cardiovasc Med Surg Pathol Pharmacol. 2018;141: 98–106.
 doi:10.1159/000493572
- Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial
 infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis.
 2009;9: 601–610. doi:10.1016/S1473-3099(09)70233-6
- Pellicori P, Doolub G, Wong CM, Lee KS, Mangion K, Ahmad M, et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database Syst Rev. 2021;2022. doi:10.1002/14651858.CD013879
- La Roi-Teeuw HM, Van Smeden M, Bos M, De Wilde SM, Yang B, Rutten FH, et al.
 Estimated causal effects of common respiratory infections on cardiovascular risk: a
 meta-analysis. Open Heart. 2023;10: e002501. doi:10.1136/openhrt-2023-002501
- 436 23. Davidson JA, Banerjee A, Douglas I, Leyrat C, Pebody R, McDonald HI, et al. Primary
 437 prevention of acute cardiovascular events by influenza vaccination: an observational
 438 study. Eur Heart J. 2023;44: 610–620. doi:10.1093/eurheartj/ehac737
- 439 24. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
 440 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ.
 441 2021; n71. doi:10.1136/bmj.n71
- 442 25. Stroup DF, Berlin JA. Meta-analysis of Observational Studies in Epidemiology: A
 443 Proposal for Reporting. Meta-analysis of Observational Studies in Epidemiology
 444 (MOOSE) group. JAMA. 2000;283: 2008. doi:10.1001/jama.283.15.2008
- PRISMA-P Group, Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, et al.
 Preferred reporting items for systematic review and meta-analysis protocols (PRISMAP) 2015 statement. Syst Rev. 2015;4: 1. doi:10.1186/2046-4053-4-1
- 448 27. British Medical Journal (BMJ) Knowledge Centre. Search strategies. In: BMJ Best
 449 Practice [Internet]. 2023 [cited 29 Dec 2023]. Available:
 450 https://bestpractice.bmj.com/info/toolkit/learn-ebm/study-design-search-filters/
- 28. Clark JM, Sanders S, Carter M, Honeyman D, Cleo G, Auld Y, et al. Improving the
 translation of search strategies using the Polyglot Search Translator: a randomized
 controlled trial. J Med Libr Assoc. 2020;108. doi:10.5195/jmla.2020.834

- 454 29. Covidence. Melbourne, Australia: Veritas Health Innovation; 2024. Available:
 455 www.covidence.org
- 456 30. The EndNote Team. EndNote. Philadelphia, PA: Clarivate; 2024.
- 457 31. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors.
 458 Cochrane Handbook for Systematic Reviews of Interventions. version 6.4. Hoboken,
 459 NJ: Wiley-Blackwell; 2023. Available: https://training.cochrane.org/handbook
- 32. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a
 revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 14898.
 doi:10.1136/bmj.14898
- 463 33. ROBINS-E Development Group (Higgins J, Morgan R, Rooney A, Taylor K, Thayer K, 464 Silva R, Lemeris C, Akl A, Arroyave W, Bateson T, Berkman N, Demers P, Forastiere F, Glenn B, Hróbjartsson A, Kirrane E, LaKind J, Luben T, Lunn R, McAleenan A, 465 466 McGuinness L, Meerpohl J, Mehta S, Nachman R, Obbagy J, O'Connor A, Radke E, 467 Savović J, Schubauer-Berigan M, Schwingl P, Schunemann H, Shea B, Steenland K, Stewart T, Straif K, Tilling K, Verbeek V, Vermeulen R, Viswanathan M, Zahm S, 468 Sterne J). Risk Of Bias In Non-randomized Studies - of Exposure (ROBINS-E). 2023. 469 470 Available: https://www.riskofbias.info/welcome/robins-e-tool
- 471 34. Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327: 557–560.
 472 doi:10.1136/bmj.327.7414.557
- 473 35. R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
 474 Austria: R Foundation for Statistical Computing; 2021. Available: https://www.R475 project.org/
- 476 36. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1.
 477 Introduction—GRADE evidence profiles and summary of findings tables. J Clin
 478 Epidemiol. 2011;64: 383–394. doi:10.1016/j.jclinepi.2010.04.026
- 479 37. UN DESA. The Sustainable Development Goals Report 2023: Special Edition July
 480 2023. New York, USA: UN DESA; 2023. Available: 481 https://unstats.un.org/sdgs/report/2023/
- 482 38. Feikin DR, Scott JAG, Gessner BD. Use of vaccines as probes to define disease burden.
 483 The Lancet. 2014;383: 1762–1770. doi:10.1016/S0140-6736(13)61682-7

485 **Supporting information**

- 486 S1 File. PRISMA-P checklist. Preferred Reporting Items for Systematic review and Meta-
- 487 analysis Protocols (PRISMA-P) checklist
- 488 S2 File. Search strategy. Search strategy for Ovid MEDLINE, Ovid Embase, PubMed,
- 489 Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science